"N Engl J Med"[journal] 检索结果

461. Tirzepatide as Compared with Semaglutide for the Treatment of Obesity.

作者: Louis J Aronne.;Deborah Bade Horn.;Carel W le Roux.;Wayne Ho.;Beverly L Falcon.;Elisa Gomez Valderas.;Sagar Das.;Clare J Lee.;Leonard C Glass.;Cagri Senyucel.;Julia P Dunn.; .
来源: N Engl J Med. 2025年393卷1期26-36页

Tirzepatide and semaglutide are highly effective medications for obesity management. The efficacy and safety of tirzepatide as compared with semaglutide in adults with obesity but without type 2 diabetes is unknown.

462. Sixty Years of Community Health Centers - An Anniversary at a Crossroads.

作者: Alexander E Jacobs.
来源: N Engl J Med. 2025年392卷19期1875-1877页

463. Efruxifermin in Compensated Liver Cirrhosis Caused by MASH.

作者: Mazen Noureddin.;Mary E Rinella.;Naga P Chalasani.;Guy W Neff.;K Jean Lucas.;Manuel E Rodriguez.;Madhavi Rudraraju.;Rashmee Patil.;Cynthia Behling.;Mark Burch.;Doreen C Chan.;Erik J Tillman.;Arian Zari.;Brittany de Temple.;Reshma Shringarpure.;Meena Jain.;Timothy Rolph.;Andrew Cheng.;Kitty Yale.
来源: N Engl J Med. 2025年392卷24期2413-2424页

In phase 2 trials involving patients with stage 2 or 3 fibrosis caused by metabolic dysfunction-associated steatohepatitis (MASH), efruxifermin, a bivalent fibroblast growth factor 21 (FGF21) analogue, reduced fibrosis and resolved MASH. Data are needed on the efficacy and safety of efruxifermin in patients with compensated cirrhosis (stage 4 fibrosis) caused by MASH.

464. Safety and Efficacy of Obicetrapib in Patients at High Cardiovascular Risk.

作者: Stephen J Nicholls.;Adam J Nelson.;Marc Ditmarsch.;John J P Kastelein.;Christie M Ballantyne.;Kausik K Ray.;Ann Marie Navar.;Steven E Nissen.;Mariko Harada-Shiba.;Danielle L Curcio.;Annie Neild.;Douglas Kling.;Andrew Hsieh.;Julie Butters.;Brian A Ference.;Ulrich Laufs.;Maciej Banach.;Roxana Mehran.;Alberico L Catapano.;Yong Huo.;Michael Szarek.;Violeta Balinskaite.;Michael H Davidson.; .
来源: N Engl J Med. 2025年393卷1期51-61页

Obicetrapib is a highly selective cholesteryl ester transfer protein inhibitor that reduces low-density lipoprotein (LDL) cholesterol levels. The efficacy and safety of obicetrapib have not been fully characterized among patients at high risk for cardiovascular events.

465. U.S. Research Leadership at a Crossroads - The Impact of Reducing NIH Indirect-Cost Coverage.

作者: Amar H Kelkar.
来源: N Engl J Med. 2025年392卷21期2081-2084页

466. Judicial Invalidation of the FDA's Laboratory-Developed Test Rule - Legal and Public Health Consequences.

作者: Rachel E Sachs.;Joshua M Sharfstein.;Patricia J Zettler.
来源: N Engl J Med. 2025年392卷20期e49页

467. More on Acquired Osteomalacia and Autoantibodies against PHEX. Reply.

作者: Yoshitomo Hoshino.;Kazuo Okamoto.;Nobuaki Ito.
来源: N Engl J Med. 2025年392卷18期1871-1872页

468. More on Acquired Osteomalacia and Autoantibodies against PHEX.

作者: Salvatore Minisola.;Jessica Pepe.;Cristiana Cipriani.
来源: N Engl J Med. 2025年392卷18期1871页

469. Vutrisiran in Patients with Transthyretin Amyloidosis with Cardiomyopathy. Reply.

作者: Marianna Fontana.;Ronald M Witteles.;Satish A Eraly.
来源: N Engl J Med. 2025年392卷18期1870-1871页

470. Vutrisiran in Patients with Transthyretin Amyloidosis with Cardiomyopathy.

作者: Mohamad Zaidan.
来源: N Engl J Med. 2025年392卷18期1870页

471. Cabozantinib in Advanced Neuroendocrine Tumors. Reply.

作者: Jennifer A Chan.;Susan Geyer.;Jeffrey A Meyerhardt.
来源: N Engl J Med. 2025年392卷18期1869-1870页

472. Cabozantinib in Advanced Neuroendocrine Tumors.

作者: Diamantis I Tsilimigras.
来源: N Engl J Med. 2025年392卷18期1869页

473. Liraglutide for Children 6 to <12 Years of Age with Obesity. Reply.

作者: Claudia K Fox.;Nina M Harder-Lauridsen.;Silva Arslanian.
来源: N Engl J Med. 2025年392卷18期1868页

474. Liraglutide for Children 6 to <12 Years of Age with Obesity.

作者: Josephine M Egan.;Dimitrios Kapogiannis.
来源: N Engl J Med. 2025年392卷18期1866-1868页

475. Liraglutide for Children 6 to <12 Years of Age with Obesity.

作者: Conghua Ji.;Minyan Wang.
来源: N Engl J Med. 2025年392卷18期1867页

476. Liraglutide for Children 6 to <12 Years of Age with Obesity.

作者: Saul Malozowski.
来源: N Engl J Med. 2025年392卷18期1866-1867页

477. Pegivirus-Associated Encephalomyelitis in Immunosuppressed Patients.

作者: Franziska Scheibe.;Julia Melchert.;Helena Radbruch.;Eberhard Siebert.;Till D Best.;Siegfried Kohler.;Mira Fitzek.;Alexander Kowski.;Volker Siffrin.;Jenny Meinhardt.;Raphael Raspe.;Viktor Horst.;Bianca Zukunft.;Klemens Budde.;Frank K H van Landeghem.;Christopher Power.;Kai-Uwe Eckardt.;Matthias Endres.;Christian Drosten.;Victor M Corman.;Klemens Ruprecht.
来源: N Engl J Med. 2025年392卷18期1864-1866页

478. Automated Insulin Pump in Type 2 Diabetes.

作者: Betul Hatipoglu.
来源: N Engl J Med. 2025年392卷18期1862-1863页

479. To BCG or Not Two BCG.

作者: Stephen M Carpenter.;W Henry Boom.
来源: N Engl J Med. 2025年392卷18期1860-1862页

480. Targeting the Tumor and the Immune System in Smoldering Multiple Myeloma.

作者: Francesco Maura.;P Leif Bergsagel.
来源: N Engl J Med. 2025年392卷18期1858-1860页

结果排序

文献格式

出版时间

出版类型

出版语言